Investor
Versant Venture Management, LLC
CIK 0001560009 · filed 2026-05-05 · SEC filing
13F book
$141.4M
Positions
8
1 new · 0 sold
Largest name
37.0%
Monte Rosa Therapeutics, Inc. · GLUE
Est. mark
−$18.3M
Price effect on 7 names still held. Flow $8.65M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | GLUE | 3.18M | $52.3M | 37.0% | $2.45M | Cut−$16.4M |
| Century Therapeutics, Inc. | IPSC | 12.2M | $27.5M | 19.4% | — | New |
| LENZ Therapeutics, Inc. | LENZ | 2.66M | $24.3M | 17.2% | −$18.2M | Held |
| Jade Biosciences, Inc. | JBIO | 1.53M | $21.4M | 15.2% | −$2.11M | Held |
| Contineum Therapeutics, Inc. | CTNM | 542.6K | $7.09M | 5.0% | $884.5K | Held |
| Crispr Therapeutics Ag | CRSP | 148.8K | $7.08M | 5.0% | −$724.8K | Held |
| Skye Bioscience, Inc. | SKYE | 2.01M | $1.23M | 0.9% | −$271.2K | Held |
| Tempest Therapeutics, Inc. | TPST | 269.8K | $442.4K | 0.3% | −$331.8K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.